Drug Profile

NTX 001

Alternative Names: NTX-001

Latest Information Update: 26 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Neuraptive Therapeutics
Class Neuroprotectants
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Peripheral nerve injuries
New Molecular Entity No

Highest Development Phases

Phase III Peripheral nerve injuries
Phase II Facial paralysis
Preclinical Epilepsy

Most Recent Events

10 Feb 2025 Phase-III clinical trials in Peripheral nerve injuries (Adjunctive treatment) in USA (Topical) (NCT06616025)
12 Sep 2024 NTX 001 receives Breakthrough Therapy status for Peripheral nerve injuries in USA
11 Sep 2024 Neuraptive Therapeutics plans a phase-III trial for peripheral nerve injury in January 2025 (Topical), (NCT06616025),

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com